

**PRESS RELEASE** 

## THE BOARD OF DIRECTORS OF SVAS BIOSANA CONSOLIDATED TURNOVER FOR THE FIRST QUARTER OF 2023

# THE COMPANY'S POSITIVE GROWTH TREND HAS CONTINUED IN Q1 WITH CONSOLIDATED REVENUES AS AT 31 MARCH 2023 OF € 26.4 MILLION WITH A 24.2% YOY INCREASE

Somma Vesuviana (Naples) 9 May 2023 – Svas Biosana S.p.A., (the "Company" or "SVAS"), a leading player in the production and distribution of medical devices for public and private healthcare facilities, and listed on Euronext Growth Milan, a multilateral trading system organised and managed by Borsa Italiana S.p.A. which focuses on small and medium-sized companies with high growth potential, announces that, on today's date, the Board of Directors met and examined the preliminary consolidated turnover as at 31 March 2023 (unaudited), which amounts to € 26.4 million, up by 24.2% on the same period of the previous year (€ 21.3 million).

The results of the individual business units may be summarised as follows:

Business Unit	Turnover as at 31/03/23	% of total	Turnover as at 31/03/22	% of total	1Q-23 vs 1Q-22
SVAS	4,3	16,2%	5,0	23,3%	-14,0%
FARMEX	8,2	30,8%	7,0	32,6%	17,1%
MEDICAL	2,2	8,3%	2,0	9,3%	10,0%
MARK MEDICAL	8,6	32,3%	7,5	34,9%	14,7%
BORMIA	3,3	12,4%	-	-	-
TOTAL AGGREGATE REVENUES	26,6	100,0%	21,5	100,0%	23,7%
Intra-group revenues	- 0,2		- 0,2		
TOTAL CONSOLIDATED REVENUES	26,4		21,3		23,9%

The consolidated turnover as at 31 March 2023 includes revenues of € 3.3 million generated by the Bormia Group, which was acquired on 23 June 2022.



According to **Umberto Perillo, CEO of Svas Biosana S.p.A.:** "Another excellent result that consolidates the positive trend and propels the company towards a 2023 of growth. The result achieved confirms the vision set by the management, which is constantly striving to transform the commitments of our ambitious Strategic Plan into numbers".

\* \* \* \* \* \* \* \*

This press release can be found at Borsa Italiana, at the Company's registered office, and in the *Financial Releases* section of the company's website <a href="https://www.svas.it">www.svas.it</a>.

Svas Biosana uses the eMarket SDIR system, managed by Teleborsa S.r.l., with registered office at Piazza di Priscilla 4, 00199, Rome (<a href="www.emarketstorage.com">www.emarketstorage.com</a>), to disclose regulated information.

\* \* \* \* \* \* \* \*

#### Contacts:

#### SVAS Biosana S.p.A.

Andrea Efficace
Group CFO and Investor Relations Manager
+39 081.8995411
a.efficace@svas.it

#### **Investor Relations Advisor**

POLYTEMS HIR Bianca FERSINI MASTELLONI - Silvia MARONGIU 06.69923324-066797849 s.marongiu@polytemshir.it

#### **Specialist**

Banca Profilo +39 02.584081

#### **Euronext Growth Advisor**

Banca Profilo
Via Cerva 128, Milan
+39 02.584081
alessio.muretti@bancaprofilo.it

#### **Media Relations Advisor**

POLYTEMS HIR
Paolo SANTAGOSTINO
+393493856585
p.santagostino@polytemshir.it

Svas Biosana manufactures and distributes medical devices in Italy and abroad. Founded in 1972 in Somma Vesuviana (NA) by the Perillo family, SVAS is now an international company with a catalogue of approximately 16,000 own and third party brand products, roughly 390 employees, a Research and Development department, 3 production facilities in Italy and subsidiaries in Slovenia, Croatia, Serbia and Bosnia-Herzegovina.

Ticker: ISIN Ordinary Shares: IT0005469264 Ticker: ISIN Warrant SVAS BIOSANA 2021-2024: IT0005469157

Companies Register of Naples no. 4543/85 Economic and Tax Code 04720630633 VAT no. 01354901215 Via M. Perillo, 34 80047 San Giuseppe Vesuviano (NA) Italy

### Correspondence

Post Box 91 80049 Somma Vesuviana (NA) Italy

### Headquarters and Via Trentola. 7

80049 Somma Vesuviana (NA) Italy Contacts

Tel. +390818995411 Fax +390818993922 www.svas.it

svasbiosana@legalmail.it